Previous Article |
Table of Contents
| Next Article
* Institute for Neurodegenerative Diseases, Departments of
Contributed by Stanley B. Prusiner, December 27, 2001
Because the insolubility of the scrapie prion protein
(PrPSc) has frustrated structural studies by x-ray
crystallography or NMR spectroscopy, we used electron
crystallography to characterize the structure of two infectious
variants of the prion protein. Isomorphous two-dimensional crystals of
the N-terminally truncated PrPSc (PrP 27-30) and a
miniprion (PrPSc106) were identified by negative stain
electron microscopy. Image processing allowed the extraction of limited
structural information to 7 Å resolution. By comparing projection maps
of PrP 27-30 and PrPSc106, we visualized the 36-residue
internal deletion of the miniprion and localized the N-linked sugars.
The dimensions of the monomer and the locations of the deleted segment
and sugars were used as constraints in the construction of models for
PrPSc. Only models featuring parallel electron microscopy|image processing|Nanogold
labeling|parallel Creutzfeldt-Jakob disease
(CJD), bovine spongiform encephalopathy (BSE), scrapie, and other
spongiform encephalopathies are caused by an aberrantly folded isoform
(PrPSc) of the prion protein (PrP) (1).
Replication of prions includes a profound change in the conformation of
the cellular isoform of PrP (PrPC) to form the
highly insoluble PrPSc. The insolubility of
PrPSc has thwarted attempts to investigate its
structure by either x-ray crystallography or NMR spectroscopy. Our
knowledge about the structure of PrPSc is
therefore rather limited (2).
After treatment with proteinase K (PK), PrPSc
loses the N-terminal residues 23 to In attempts to simplify the structural analysis of
PrPSc, we systematically deleted parts of the
prion protein. One of these constructs containing only 106 residues,
PrP106 ( Here we report the discovery of two-dimensional (2D) crystals of PrP
27-30 and PrPSc106. Electron micrographs of the
crystals were analyzed by digital image processing and found to have
three-fold symmetry. The complexation of heavy metal cations onto the
crystal lattice indicated the presence of a strong negative
electrostatic potential in the center of individual oligomers. Specific
labeling of the N-linked sugars with Monoamino Nanogold
(Nanoprobes, Yaphank, NY) enabled us to localize them toward the
outside of the oligomer. Crystals of PrPSc106,
isomorphous to the crystals of PrP 27-30, permitted the determination of significant differences between the two structures. Difference mapping revealed the location of the 36-residue internal deletion of
the miniprion in projection. These data were coupled with a variety of
other experimental results to create constraints on plausible models
for the structure of PrPSc. Only models featuring
a parallel Negative Stain Electron Microscopy.
The negative staining and electron microscopy (EM) were performed as
described (22). Electron micrographs used for image processing were
recorded at a magnification of 80,000 and an electron dose of Image Processing.
Negatives of suitable 2D crystals were scanned on a Perkin-Elmer PDS
microdensitometer with a pixel size of 20 µm (equivalent to 2.5 Å per pixel). A contrast transfer function (CTF) correction was applied
by using the CRISP software package (23). In some cases,
CRISP was also used to partially compensate for the
dampening of the CTF function toward higher resolution. The
CTF-corrected images were processed by using correlation-mapping and
averaging routines written for the SPIDER and
WEB software package (24). A manually chosen 128 × 128 pixel reference was cross-correlated to same-size subsets of the
image in a rotational and translational search. After multiple
iterations, the algorithm converged and no further improvements could
be achieved. The aligned subsets of the CTF-corrected micrograph were
examined by correspondence analysis (24) to ensure that only a
homogeneous population of images was used. Finally, the data of the
original electron micrograph were divided into 10 sectors and averaged
separately. These 10 averages were then used for plane group analysis
and crystallographic averaging. The 10 crystallographic subaverages
were combined into one final average.
Labeling of the N-Linked Sugars.
The labeling procedure was modified after Lipka et al. (25).
Suspensions of PrP 27-30 2D crystals were oxidized (10 mM
NaIO4/100 mM NaHepes, pH 7.0) for 2 h
at room temperature (RT). The protein was kept in suspension by
end-over-end rotating. After the oxidation, the protein was pelleted
and resuspended in carbonate buffer (100 mM sodium carbonate, pH 9.0).
An excess of 1.4 nm Monoamino Nanogold (Nanoprobes) was suspended in
carbonate buffer and added to the protein. The oxidized 2D crystals and
the Monoamino Nanogold were reacted for 2 h at RT under constant
rotation. The reaction was brought to completion by adding a small
aliquot of 5 M NaBH4 in 0.1 M NaOH. This reaction
was allowed to sit undisturbed for 30 min at RT. Finally, the protein
was pelleted, the unbound gold label was discarded with the
supernatant, and the pellet was resuspended in buffer. Controls were
treated identically with the exception that no Monoamino Nanogold was added.
The sugar residues within the glycosylphosphatidylinositol (GPI) anchor
made it necessary to establish that the label was indeed bound to the
N-linked sugars. We denatured gold-labeled PrP 27-30 and treated it
with PNGase F. Western blots of unlabeled, labeled, and enzyme-treated
samples were developed with the 3F4 Ab or a silver enhancement kit that
directly visualized the gold label on the blotting membrane. The
labeled samples showed an additional band at Image Processing of Labeled Crystals.
The image processing routine, as developed for unlabeled 2D crystals,
tended to cancel out the signal of the Nanogold particles because the
alignment procedure favored lattice-derived signals over the somewhat
irregular gold labels. After the iterative alignment procedure, we used
correspondence analysis (24) to eliminate the contributions of
unlabeled subunits. Furthermore, we separated four different classes of
partially labeled subunits, calculated the average for each class, and
then used those averages for subsequent crystallographic averaging.
Modeling.
Models were built by using SWISS-PDB-VIEWER software (26).
Briefly, the PrP structure was threaded onto known 2D Crystals of PrP 27-30.
Negative stain EM revealed the presence of 2D protein crystals in some
preparations of PrP 27-30 (Fig.
1A). During the purification of PrP 27-30, most of the protein polymerized into "prion rods," typical amyloid polymers that revealed little structural detail (3, 4).
The final step of this purification procedure used a sucrose gradient
centrifugation (3). We discovered that some fractions contain prion
rods and 2D crystals (Fig. 1A) with an apparent
hexagonal lattice (a and b = 69 Å;
Biophysics
Structural studies of the scrapie prion protein by
electron crystallography
,
,
,
,**,
,§,
,
,§,
Neurology,
Cellular and Molecular
Pharmacology, § Biochemistry and Biophysics, and

Medicine, and ¶ The Howard Hughes Medical
Institute, University of California, San Francisco, CA 94143
![]()
Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-helices as the
key element could satisfy the constraints. These low-resolution
projection maps and models have implications for understanding prion
propagation and the pathogenesis of neurodegeneration.
-helix|amyloid structure
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
89 (forming PrP 27-30), but
retains infectivity. During purification, PrP 27-30 polymerizes into
rod-shaped filaments with the tinctorial properties of amyloid (3, 4).
X-ray fibril diffraction illustrated the amyloid nature of PrP 27-30; characteristic 4.7 Å reflections indicative of cross-
structure were observed (5). Optical spectroscopy revealed that
PrPSc and PrP 27-30 are substantially enriched in
-sheet structure (6-9). This finding is in sharp contrast to the
predominantly
-helical fold of the three-helix-bundle structure of
PrPC as determined by NMR spectroscopy and
x-ray crystallography on refolded recombinant PrP (10-18). Owing to
the lack of high-resolution structural information for
PrPSc, predictive methods have been used to
develop molecular models to codify the existing spectroscopic,
immunological, and biochemical data (19).
23-88,
141-176), supported the propagation of prions
(20, 21). Transgenic mice expressing only PrP106 develop a
histologically accurate neurodegenerative prion disease after
inoculation with prions, and the resulting prions can be serially
passaged (21).
-helix as the key element could satisfy all of these constraints.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
25
pA/cm2 (equivalent to
100
electrons/Å2).
45 kDa that was
detected by both 3F4 and the silver enhancement, indicating that this
band corresponded to the gold-labeled PrP 27-30 (data not shown).
Treatment with PNGase F removed the gold label, thus showing that the
Nanogold label indeed specifically bound to the N-linked sugars.
-helical structures in all possible registers, and models were built with the
helices packed against all possible sides. The models that provided the
most stericly reasonable faces for assembly and electrostatic surfaces
that most closely resembled the observed negative staining were
selected. In addition, an effort was made to preserve the location of
secondary structural elements predicted by a variety of methods
(27-29) or indicated by experimental observation. Figures were created
with SWISS-PDB-VIEWER and RASMOL.
![]()
Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
= 120° as
determined by electron diffraction).

View larger version (167K):
[in a new window]
Fig. 1.
2D crystals of PrP 27-30. (A) A 2D crystal of PrP 27-30 stained with 2% uranyl acetate showing an apparent hexagonal lattice.
(B) High power view of a crystal after CTF correction
and several rounds of correlation-mapping and averaging.
(C) Section of a power spectrum after averaging showing
spots out to the 11th order, corresponding to
7 Å (arrow).
(D) Crystallographic averaging further improved the
amount of detail visible. A p3 plane group was used. (E)
Typical prion rod with an aggregate of "crystal" subunits at each
end. Some protofilaments reveal rows of dense stain accumulations,
suggesting stacked subunits (arrowheads). [Bars = 100 nm.]
Immunogold labeling with anti-PrP mAbs R1, R2, 3F4, and 28D established that PrP is an integral part of these crystals (data not shown). Decoration with 3F4 could be achieved only after urea denaturation, arguing that the scrapie isoform is present in these crystals, because 3F4 recognizes an epitope that is inaccessible in native PrPSc (30, 31). Furthermore, the 2D crystals originated in preparations that had high titers of infectivity and had not been treated by denaturing agents. Therefore, we consider the crystals to be fully infectious. Moreover, we frequently observed 2D crystals in the direct vicinity of the prion rods and on occasion what appeared to be transitions between them (Fig. 1E). These transitional aggregates suggest a stacking of the disk-like oligomers into "protofilaments."
The 2D crystals can be visualized with negative stains such as uranyl acetate (Fig. 1A). Various heavy metal stains, including other uranyl salts, cerium chloride, and ammonium molybdate stained the crystals equally well (data not shown). We reported on 2D crystals of PrP 27-30 that were obtained from reverse micelles but that lacked infectivity (32). Unlike the crystals described here, those noninfectious crystals strictly depended on divalent uranyl cations for crystallization.
The dark areas in the center of the current 2D crystal subunits (Fig. 1 A and E) are caused by a complexation of uranyl ions (or other heavy metal cations) to negative charges within the crystal lattice, effecting a positive stain. The nature of the complex formation became apparent when uranyl salts that differ greatly in their stability constants (pK) were used. For example, uranyl acetate and oxalate produced the typical staining pattern seen in Fig. 1A. In contrast, uranyl citrate generated a very different result with no apparent staining of the subunit centers (data not shown). The pK values for uranyl acetate, oxalate, and citrate are 3.2, 6.5, and 18.9, respectively (33). Thus, we know that the uranyl·PrP 27-30 complex has an effective pK greater than 6.5 but less than 18.9. The observation that anionic stains, like molybdate, were repelled from the center of the subunits (data not shown) allowed us to conclude that a cluster of partial or full negative charges occupies the center of each oligomer. The sequence of PrP 27-30 contains several negatively charged residues that may contribute to the observed complexation of heavy metal cations; the highest concentration of these residues lies between amino acids 143 and 177.
Image Processing.
To obtain images suitable for digital processing, we took electron
micrographs of the 2D crystals at underfocus values lower than those of
conventional negative stain images. The high contrast of the negatively
stained crystals enabled us to process images with 200-300 nm of
underfocus, as determined from the Thon rings of Fourier transforms.
Because of the limited quality and small size of the crystals, the
images were processed with correlation methods that are used routinely
for single-particle reconstructions. A region containing several unit
cells was correlated throughout the crystal, and appropriate rotations
and translations were applied to correct for local lattice
imperfections. Fig. 1B shows the results after several
rounds of iterative correlation-mapping and averaging. The power
spectrum showed spots out to the 11th order, which corresponds to
7
Å spacing (Fig. 1C).
Crystallographic averaging exploits the symmetry relationships within the Fourier transforms of individual images. The amplitude R factors and phase residuals for a 2D crystal processed for the relevant plane groups indicate a p3 plane group as the most likely symmetry (Table 1). Thus, we routinely applied p3 symmetry during crystallographic averaging (Fig. 1D). Because rotational cross-correlation demonstrated six distinct densities within each subunit (data not shown), we presuppose either a trimer of dimers arrangement for the unit cell with a noncrystallographic dimer axis or a trimeric arrangement, in which each subunit has two centers of density. The trimeric arrangement would give the unit cell a polarity that should be noticeable within the crystals and could result in a polar filament assembly. As neither of these features was observed at the current resolution, we favor the trimer of dimers interpretation.
|
Localization of the Sugar Side Chains.
To localize the N-linked sugars of PrP 27-30, we specifically labeled the oligosaccharides by 1.4-nm gold particles (Nanogold). The procedure succeeded in labeling the preformed crystals without affecting prion infectivity (data not shown).
The high contrast of uranyl acetate staining made it difficult to visualize the small label (Fig. 2A). The image processing on labeled crystals (Fig. 2 A and B) revealed some differences, but the procedure required additional refinements to detect the somewhat nonperiodic labels. Because the crystallographic averaging used p3 symmetry, the procedure may have systematically underestimated the number of locations for the gold label by a factor of 2. The subtraction map did indeed show some weak differences at the second three-fold axis (Fig. 2C). By subtracting 3 times the value of the standard error map, we obtained statistically significant differences that when overlaid onto the average of an unlabeled crystal, showed the sugar side chains located toward the outside of the oligomers (Fig. 2D). This peripheral localization provides a constraint on the orientation of the protein molecules within the crystal lattice.
|
The N-linked sugars of hamster PrP 27-30 are bound to residues N181 and
N197. In the solution structure of recombinant
PrPC, these residues lie in helix B and near the
N terminus of helix C, respectively (10-17). Theoretical
considerations and experimental evidence indicate that helices B
(residues 179-193) and C (residues 200-217) in
PrPC are preserved in PrPSc
(19). Fourier transform infrared spectroscopy of PrP 27-30 and
PrPSc106 demonstrated substantial residual
-helical structure (23% and 27-31%, respectively) (21, 22),
whereas epitope mapping localized the conformational change that
characterizes PrPSc to the region between
residues 90 and 170 (34). Synthetic peptides corresponding to
PrP(90-145,P101L) have been shown to refold into a
-sheet-rich
state that can initiate or accelerate prion disease in specific
transgenic mice (35), reinforcing the notion that the formation of
-structure in PrPSc is unlikely to involve the
C-terminal helices. Thus, residues N181 and N197 are expected to be
closely linked to the remaining helical regions of
PrPSc. As these segments are joined by a
disulfide bridge (C179-C214) that is retained in
PrPSc and required for infectivity (20), it is
likely that the
-helices of PrPSc will be
located toward the outside of the oligomers as well.
The relatively small lattice parameters and the accordingly dense
packing of the protein molecules in the trimer of dimers arrangement
would require the sugars to protrude up and down from the lattice. The
projection map alone does not allow us to confirm whether the sugars
are in or out of the plane of the protein moiety. The less dense
packing of a trimeric assembly would give the sugars additional room in
the lattice. The intrinsic flexibility of the sugar side chains of PrP
may allow them to rotate in and out of the lattice plane, depending on
steric constraints (36). This notion is supported by the observation
that Nanogold-labeled prion rods show a relatively dense covering of
gold labels on the surface of the rods (data not shown). This result in
turn suggests that the lateral association of "protofilaments"
into prion rods is influenced
if not dominated
by the N-linked
sugars. Furthermore, steric hindrance by the oligosaccharides could
account for the inaccessibility of prion rods to various enzymatic digestions.
Differences Between PrP 27-30 and PrPSc106.
While analyzing preparations of PrPSc106 miniprions by negative stain EM, we observed both rod-like polymers (21) and 2D crystals isomorphous to those seen with PrP 27-30 (Fig. 3A). This finding enabled us to use the same image processing strategies used for the PrP 27-30 crystals (Figs. 1D and 3B), and map the differences between PrP 27-30 and PrPSc106.
|
PrPSc106 lacks residues 141-176 but is consistently diglycosylated (20, 21). By comparison, PrP 27-30 has a longer peptide chain and is a mix of un-, mono-, and diglycosylated forms (36). As these crystals display a complex mixture of negative and positive staining, it is important to consider the staining behavior of the different constructs. PrPSc106 lacks many of the negatively charged residues that are present in PrP 27-30 and hence binds fewer uranyl cations at the center of the subunits (data not shown). Therefore, subtracting the PrP 27-30 density from the PrPSc106 density should highlight residues 141-176 in positive density, whereas subtracting PrPSc106 from PrP 27-30 should place the extra glycosylation sites in positive density.
As expected, PrP 27-30 minus PrPSc106 showed
differences that were nearly identical to the location of the sugars
determined by Nanogold labeling (Figs. 2D and
3F). Here the difference signal for the N-linked sugars was
found on all three-fold symmetry axes around the oligomer (Fig.
3F). PrPSc106 minus PrP 27-30 revealed
differences around the center of each oligomer (Fig. 3E),
which we interpret as being representative of the amino acids in the
internal deletion of PrP106 (
141-176).
Fourier transform infrared spectroscopy indicates a
-sheet content
of
48% for PrP 27-30 (
68 of 142 residues) and
37% for PrPSc106 (
39 of 106 residues) when measured
under identical conditions (21, 22). By comparing these percentages, we
conclude that most of the 36 residues of the internal deletion adopt a
-sheet conformation in the scrapie isoform. We therefore infer that
the difference between PrP 27-30 and PrPSc106
visualized in our 2D crystals (Fig. 3E) actually represents predominantly
-sheet structure.
In the solution structure of recombinant PrPC,
residues 141 and 176 are separated by
18 Å with helix C physically
intervening between the two residues (10-17). That PrP 27-30 and
PrPSc106 form isomorphous 2D crystals requires
residues 140 and 177 to be in close proximity to each other in the
scrapie conformation. Thus, a two- or four-stranded
-sheet motif
with spatially proximal termini like a
-hairpin, a
-meander, a
Greek key motif, or two turns of a parallel
-helix are plausible
structural arrangements.
Models of PrPSc.
Previous endeavors to model the structure of
PrPSc attempted to fit sequence-specific
conformational preferences with spectroscopic, antibody-binding, and
other biological data. Originally, we postulated an anti-parallel
-sheet formed from residues 90 to 170 packed against the two
C-terminal
-helices (19). The results obtained from the 2D crystals
described here, the existence of PrPSc106
(implying the spatial colocalization of residues 140 and 177), and
increasing data pointing to parallel
-sheet structure in amyloid-forming proteins (37, 38) caused us to revisit this model (19).
A single anti-parallel
-sheet was not consistent with the observed
densities in the projection maps obtained from the 2D crystals.
Specifically, the sheets were far too wide to fit into the observed
hexameric arrangement. Efforts to adjust the sheet morphology to fit
the density required the use of shorter strands. The amount of
-structure in these altered
-sheets was no longer compatible with
the amounts of
-sheet observed by Fourier transform infrared
spectroscopy (21, 22). Furthermore, anti-parallel
-sheets typically
have a twist of
20° per strand. A six- to eight-stranded
-sheet
would be difficult to accommodate in the electron density. Parallel
-sheets are commonly observed in protein structures as part of
planar
/
folds,
/
barrels, and parallel
-helices. Planar
/
folds encounter the same problems
as twisted anti-parallel
-sheets.
/
barrels have
alternating
-helices and
-strands with the fraction of
-helical residues exceeding that of the
-stranded residues. The
secondary structure content of these folds would be in conflict
with the FTIR results for both PrP 27-30 and
PrPSc106. Although we cannot exclude a novel
protein fold for the structure of PrPSc, the
parallel
-helix is the only known fold that provides the necessary
-sheet content, parallel
-architecture, and room to accommodate
the
-helices that are expected at the C-terminus of the molecule.
A number of proteins natively form parallel
-helices and exist as
soluble monomers or low-order oligomers (39-42). This fold is
considered unusually stable, and mutants of these proteins have been
observed to form amyloid (43). There are essentially two types of
parallel
-helical folds: the left- and right-handed
-helices.
Proteins of either type are known to contain highly ordered, stacked
side chains on both the inside and outside of the
-helices (41).
This side-chain stacking adds to the rigid geometry of the
-helices,
which tend to have planar sides and essentially no interstrand twist
(41). The number of residues per
-helical turn can vary
substantially for right-handed
-helices (39, 41, 42), whereas an
average of 18 residues per helical turn is found in the known
left-handed
-helical structures (40).
We modeled PrPSc as a parallel
-helical fold
(Fig. 4 A and E),
placing the structurally conserved C-terminal
-helices and the
glycosylation sites (N181 and N197) on the periphery of the oligomer
and with the highly flexible N-linked sugars pointing above and below
the plane of the oligomer (Fig. 4 D and H). In this conformation, PrPSc is compact (Fig. 4
C and G) and fits readily into the density observed by EM. Because there is very little twist or bend to parallel
-helices, the modeled oligomers have relatively planar faces that
permit stacking along the fibril axis. The
-helices also provide
flat sheets for lateral assembly into disk-like oligomers and
filamentous assemblies (42, 43). The deletion of 36 residues in
PrP106 correlates favorably with exactly two turns of an average left-handed
-helix. Therefore, the orientation of the
- and
-helices, the sugars, as well as the fold of the oligomeric face, could be retained in this deletion mutant. This would allow full-length PrPSc as well as PrPSc106
to template the replication of PrPSc106.
Furthermore, the shape and location of the
-helical deletions in our
models are consistent with the difference densities observed between
the 2D crystals of PrP 27-30 and PrPSc106.
Finally, the PrP sequence can be threaded onto the
-helical folds in
a register that is consistent with secondary structure predictions,
mutational information, and the negative electrostatic potential at the
center of the oligomers.
|
| |
Discussion |
|---|
|
|
|---|
We report the discovery of 2D crystals in purified infectious fractions of PrP 27-30 and PrPSc106 by negative stain EM. The 2D crystals were found exclusively in preparations that contain high titers of prion infectivity. Because crystals were found in close proximity to prion rods (Fig. 1E) and the Ab 3F4 recognized them only after urea treatment (data not shown), we conclude that the crystals contain the infectious isoform of the prion protein.
Power spectra of digitally processed images showed spots out to the
11th order at
7 Å (Fig. 1C). Because the micrographs were taken with high doses of electrons, we were surprised to obtain
such high-resolution data. Given that the stained crystals bound heavy
metal cations in the center of their subunits, we suspect that the
high-resolution information is limited to those areas. In addition, the
presence of heavy metal cations may have provided some partial
protection against irradiation damage. The current data are limited to
projection maps only; a three-dimensional reconstruction will give more
detailed insight into the structure of PrPSc. The
future use of low-dose cryoelectron crystallography may allow us to
solve the structure of this heretofore intractable isoform.
The observed crystals were obtained from preparations of different prion strains and PrP constructs: Syrian hamster (SHa) Sc237 prions (Fig. 2; Table 1), mouse (Mo) RML prions (Fig. 1), and chimeric mouse-hamster (MHM2) RML-PrP106 prions (Fig. 3 A and B). Prion strains seem to be enciphered in the conformation of PrPSc and domain swapping has been offered as a structural explanation for the existence of several isoenergetic PrPSc structures (31, 44-49). A direct comparison of the Sc237 and RML prions used in this study is difficult owing to the eight-residue differences between the hamster and mouse sequences.
In summary, we report that PrP 27-30 has the ability to form 2D
crystals, the subunits of which expose a cluster of negative charges at
their center that are involved in the complexation of heavy metal
cations. By image subtraction, we were able to localize the N-linked
sugars of PrP 27-30 toward the periphery of the crystal subunits.
Additionally, internally deleted PrPSc106 forms
2D crystals that are isomorphous to those of PrP 27-30; difference
mapping between PrP 27-30 and PrPSc106 revealed
the location of the 36-residue internal deletion at the inside of the
oligomer. Optical spectroscopy suggested that these 36 residues are
predominantly in a
-sheet conformation (21, 22). The isomorphism of
the PrP 27-30 and PrPSc106 crystals implies a
close proximity between residues 140 and 177 in both proteins,
consistent with a
-sheet-rich fold such as a parallel
-helix. By
combining these new constraints with other experimental data, we can
exclude many structural motifs and argue that
PrPSc is likely to contain a parallel
-helix.
The parallel
-helix that we propose for PrPSc
(Fig. 4) is considered an unusually stable fold, and is generally found
in proteins subjected to harsh, denaturing environments such as
bacterial or viral virulence factors or plant pollens (41).
Furthermore, the fold is very simple and may form in a two-state manner
analogous to
-helix formation (42). Thus, the conversion from
PrPC to PrPSc can be
understood as a stabilization of a proto-
-helical motif by a
neighboring PrPSc molecule and subsequent
extension to form the complete
-helix.
| |
Acknowledgements |
|---|
We thank Robert M. Stroud, Zoltan F. Kanyo, Vinzenz Unger, and Sven Hovmöller for their advice on crystallography and computational issues; Sebastian Doniach for suggesting the trimer of dimers arrangement; John M. Chandonia for assistance with structural threading; Pauline M. Rudd for discussions on the glycosylphosphatidylinositol-anchor and N-linked sugars; Susanne D. Erpel and Diane Latawiec for expert technical assistance; Kenneth H. Downing for access to the microdensitometer; and Mei-Lie Wong for making darkroom facilities available. M.D.M. acknowledges a National Science Foundation predoctoral fellowship. V.G. was supported by a Howard Hughes postdoctoral fellowship. S.S. was supported by a Burroughs Wellcome Fund Career Development Award and a National Institutes of Health Clinical Investigator Development Award. This work was supported by grants from the National Institutes of Health and a gift from the G. Harold and Leila Y. Mathers Charitable Foundation.
| |
Abbreviations |
|---|
PrP, prion protein; PrPC, normal cellular isoform; PrPSc, disease-associated isoform; PrP 27-30, N-terminally truncated PrPSc; 2D, two-dimensional; EM, electron microscopy; CTF, contrast transfer function.
| |
Footnotes |
|---|
Present address: MVTechnology, Dublin 2, Ireland.
** Present address: Dartmouth Medical School, Hanover, NH 03755.

To whom reprint requests should be addressed.
E-mail: stanley{at}itsa.ucsf.edu.
| |
References |
|---|
|
|
|---|
| 1. |
Prusiner, S. B.
(1998)
Proc. Natl. Acad. Sci. USA
95,
13363-13383 |
| 2. | Cohen, F. E. & Prusiner, S. B. (1999) in Prion Biology and Diseases, ed. Prusiner, S. B. (Cold Spring Harbor Lab. Press, Plainview, NY), pp. 191-228. |
| 3. |
Prusiner, S. B.
, McKinley, M. P.
, Bowman, K. A.
, Bolton, D. C.
, Bendheim, P. E.
, Groth, D. F.
& Glenner, G. G.
(1983)
Cell
35,
349-358[CrossRef][ISI][Medline]
|
| 4. |
McKinley, M. P.
, Meyer, R. K.
, Kenaga, L.
, Rahbar, F.
, Cotter, R.
, Serban, A.
& Prusiner, S. B.
(1991)
J. Virol.
65,
1340-1351 |
| 5. |
Nguyen, J. T.
, Inouye, H.
, Baldwin, M. A.
, Fletterick, R. J.
, Cohen, F. E.
, Prusiner, S. B.
& Kirschner, D. A.
(1995)
J. Mol. Biol.
252,
412-422[CrossRef][ISI][Medline]
|
| 6. |
Caughey, B. W.
, Dong, A.
, Bhat, K. S.
, Ernst, D.
, Hayes, S. F.
& Caughey, W. S.
(1991)
Biochemistry
30,
7672-7680[CrossRef][Medline]
|
| 7. |
Gasset, M.
, Baldwin, M. A.
, Fletterick, R. J.
& Prusiner, S. B.
(1993)
Proc. Natl. Acad. Sci. USA
90,
1-5 |
| 8. |
Pan, K.-M.
, Baldwin, M.
, Nguyen, J.
, Gasset, M.
, Serban, A.
, Groth, D.
, Mehlhorn, I.
, Huang, Z.
, Fletterick, R. J.
, Cohen, F. E.
& Prusiner, S. B.
(1993)
Proc. Natl. Acad. Sci. USA
90,
10962-10966 |
| 9. |
Safar, J.
, Roller, P. P.
, Gajdusek, D. C.
& Gibbs, C. J., Jr.
(1993)
J. Biol. Chem.
268,
20276-20284 |
| 10. |
Riek, R.
, Hornemann, S.
, Wider, G.
, Billeter, M.
, Glockshuber, R.
& Wüthrich, K.
(1996)
Nature (London)
382,
180-182[CrossRef][Medline]
|
| 11. |
Donne, D. G.
, Viles, J. H.
, Groth, D.
, Mehlhorn, I.
, James, T. L.
, Cohen, F. E.
, Prusiner, S. B.
, Wright, P. E.
& Dyson, H. J.
(1997)
Proc. Natl. Acad. Sci. USA
94,
13452-13457 |
| 12. |
James, T. L.
, Liu, H.
, Ulyanov, N. B.
, Farr-Jones, S.
, Zhang, H.
, Donne, D. G.
, Kaneko, K.
, Groth, D.
, Mehlhorn, I.
, Prusiner, S. B.
& Cohen, F. E.
(1997)
Proc. Natl. Acad. Sci. USA
94,
10086-10091 |
| 13. |
Liu, H.
, Farr-Jones, S.
, Ulyanov, N. B.
, Llinas, M.
, Marqusee, S.
, Groth, D.
, Cohen, F. E.
, Prusiner, S. B.
& James, T. L.
(1999)
Biochemistry
38,
5362-5377[CrossRef][Medline]
|
| 14. |
Calzolai, L.
, Lysek, D. A.
, Güntert, P.
, von Schroetter, C.
, Riek, R.
, Zahn, R.
& Wüthrich, K.
(2000)
Proc. Natl. Acad. Sci. USA
97,
8340-8345 |
| 15. |
García, F. L.
, Zahn, R.
, Riek, R.
& Wüthrich, K.
(2000)
Proc. Natl. Acad. Sci. USA
97,
8334-8339 |
| 16. |
Zahn, R.
, Liu, A.
, Lührs, T.
, Riek, R.
, von Schroetter, C.
, López García, F.
, Billeter, M.
, Calzolai, L.
, Wider, G.
& Wüthrich, K.
(2000)
Proc. Natl. Acad. Sci. USA
97,
145-150 |
| 17. |
Zhang, Y.
, Swietnicki, W.
, Zagorski, M. G.
, Surewicz, W. K.
& Sönnichsen, F. D.
(2000)
J. Biol. Chem.
275,
33650-33654 |
| 18. |
Knaus, K. J.
, Morillas, M.
, Swietnicki, W.
, Malone, M.
, Surewicz, W. K.
& Yee, V. C.
(2001)
Nat. Struct. Biol.
8,
770-774[CrossRef][ISI][Medline]
|
| 19. |
Huang, Z.
, Prusiner, S. B.
& Cohen, F. E.
(1995)
Folding Des.
1,
13-19[CrossRef][Medline]
|
| 20. |
Muramoto, T.
, Scott, M.
, Cohen, F. E.
& Prusiner, S. B.
(1996)
Proc. Natl. Acad. Sci. USA
93,
15457-15462 |
| 21. |
Supattapone, S.
, Bosque, P.
, Muramoto, T.
, Wille, H.
, Aagaard, C.
, Peretz, D.
, Nguyen, H.-O. B.
, Heinrich, C.
, Torchia, M.
, Safar, J.
,
et al.
(1999)
Cell
96,
869-878[CrossRef][ISI][Medline]
|
| 22. |
Wille, H.
, Zhang, G.-F.
, Baldwin, M. A.
, Cohen, F. E.
& Prusiner, S. B.
(1996)
J. Mol. Biol.
259,
608-621[CrossRef][ISI][Medline]
|
| 23. |
Hovmöller, S.
(1992)
Ultramicroscopy
41,
121-135[CrossRef][ISI] |
| 24. |
Frank, J.
, Radermacher, M.
, Penczek, P.
, Zhu, J.
, Li, Y.
, Ladjadj, M.
& Leith, A.
(1996)
J. Struct. Biol.
116,
190-199[CrossRef][ISI][Medline]
|
| 25. |
Lipka, J. J.
, Hainfeld, J. F.
& Wall, J. S.
(1983)
J. Ultrastruct. Res.
84,
120-129[CrossRef][ISI][Medline]
|
| 26. |
Guex, N.
& Peitsch, M. C.
(1997)
Electrophoresis
18,
2714-2723[CrossRef][ISI][Medline]
|
| 27. |
Rost, B.
& Sander, C.
(1993)
J. Mol. Biol.
232,
584-599[CrossRef][ISI][Medline]
|
| 28. |
Garnier, J.
, Gibrat, J. F.
& Robson, B.
(1996)
Methods Enzymol.
266,
540-553[ISI][Medline]
|
| 29. |
Chandonia, J. M.
& Karplus, M.
(1999)
Proteins
35,
293-306[CrossRef][ISI][Medline]
|
| 30. |
Peretz, D.
, Williamson, R. A.
, Matsunaga, Y.
, Serban, H.
, Pinilla, C.
, Bastidas, R. B.
, Rozenshteyn, R.
, James, T. L.
, Houghten, R. A.
, Cohen, F. E.
,
et al.
(1997)
J. Mol. Biol.
273,
614-622[CrossRef][ISI][Medline]
|
| 31. |
Safar, J.
, Wille, H.
, Itri, V.
, Groth, D.
, Serban, H.
, Torchia, M.
, Cohen, F. E.
& Prusiner, S. B.
(1998)
Nat. Med.
4,
1157-1165[CrossRef][ISI][Medline]
|
| 32. |
Wille, H.
& Prusiner, S. B.
(1999)
Biophys. J.
76,
1048-1062 |
| 33. | Martell, A. E. & Smith, R. M. (1974) Critical Stability Constants (Plenum, New York). |
| 34. |
Williamson, R. A.
, Peretz, D.
, Pinilla, C.
, Ball, H.
, Bastidas, R. B.
, Rozenshteyn, R.
, Houghten, R. A.
, Prusiner, S. B.
& Burton, D. R.
(1998)
J. Virol.
72,
9413-9418 |
| 35. |
Kaneko, K.
, Ball, H. L.
, Wille, H.
, Zhang, H.
, Groth, D.
, Torchia, M.
, Tremblay, P.
, Safar, J.
, Prusiner, S. B.
, DeArmond, S. J.
, Baldwin, M. A.
& Cohen, F. E.
(2000)
J. Mol. Biol.
295,
997-1007[CrossRef][ISI][Medline]
|
| 36. |
Rudd, P. M.
, Wormald, M. R.
, Wing, D. R.
, Prusiner, S. B.
& Dwek, R. A.
(2001)
Biochemistry
40,
3759-3766[CrossRef][Medline]
|
| 37. |
Benzinger, T. L. S.
, Gregory, D. M.
, Burkoth, T. S.
, Miller-Auer, H.
, Lynn, D. G.
, Botto, R. E.
& Meredith, S. C.
(1998)
Proc. Natl. Acad. Sci.
95,
13407-13412 |
| 38. |
Antzutkin, O. N.
, Balbach, J. J.
, Leapman, R. D.
, Rizzo, N. W.
, Reed, J.
& Tycko, R.
(2000)
Proc. Natl. Acad. Sci.
97,
13045-13050 |
| 39. |
Yoder, M. D.
, Keen, N. T.
& Jurnak, F.
(1993)
Science
260,
1503-1507 |
| 40. |
Raetz, C. R.
& Roderick, S. L.
(1995)
Science
270,
997-1000 |
| 41. |
Jenkins, J.
, Mayans, O.
& Pickersgill, R.
(1998)
J. Struct. Biol.
122,
236-246[CrossRef][ISI][Medline]
|
| 42. |
Seckler, R.
(1998)
J. Struct. Biol.
122,
216-222[CrossRef][ISI][Medline]
|
| 43. |
Schuler, B.
, Rachel, R.
& Seckler, R.
(1999)
J. Biol. Chem.
274,
18589-18596 |
| 44. |
Bessen, R. A.
& Marsh, R. F.
(1994)
J. Virol.
68,
7859-7868 |
| 45. |
Telling, G. C.
, Parchi, P.
, DeArmond, S. J.
, Cortelli, P.
, Montagna, P.
, Gabizon, R.
, Mastrianni, J.
, Lugaresi, E.
, Gambetti, P.
& Prusiner, S. B.
(1996)
Science
274,
2079-2082 |
| 46. |
Scott, M. R.
, Groth, D.
, Tatzelt, J.
, Torchia, M.
, Tremblay, P.
, DeArmond, S. J.
& Prusiner, S. B.
(1997)
J. Virol.
71,
9032-9044[Abstract] |
| 47. |
Cohen, F. E.
& Prusiner, S. B.
(1998)
Annu. Rev. Biochem.
67,
793-819[CrossRef][ISI][Medline]
|
| 48. |
Wadsworth, J. D. F.
, Hill, A. F.
, Joiner, S.
, Jackson, G. S.
, Clarke, A. R.
& Collinge, J.
(1999)
Nat. Cell Biol.
1,
55-59[CrossRef][ISI][Medline]
|
| 49. |
Peretz, D.
, Scott, M.
, Groth, D.
, Williamson, A.
, Burton, D.
, Cohen, F. E.
& Prusiner, S. B.
(2001)
Protein Sci.
10,
854-863 |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
A. L. Lau, A. Y. Yam, M. M. D. Michelitsch, X. Wang, C. Gao, R. J. Goodson, R. Shimizu, G. Timoteo, J. Hall, A. Medina-Selby, et al. Characterization of prion protein (PrP)-derived peptides that discriminate full-length PrPSc from PrPC PNAS, July 10, 2007; 104(28): 11551 - 11556. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Maas, M. Geissen, M. H. Groschup, R. Rost, T. Onodera, H. Schatzl, and I. M. Vorberg Scrapie Infection of Prion Protein-deficient Cell Line upon Ectopic Expression of Mutant Prion Proteins J. Biol. Chem., June 29, 2007; 282(26): 18702 - 18710. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Papapostolou, A. M. Smith, E. D. T. Atkins, S. J. Oliver, M. G. Ryadnov, L. C. Serpell, and D. N. Woolfson Engineering nanoscale order into a designed protein fiber PNAS, June 26, 2007; 104(26): 10853 - 10858. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Deleault, B. T. Harris, J. R. Rees, and S. Supattapone From the Cover: Formation of native prions from minimal components in vitro PNAS, June 5, 2007; 104(23): 9741 - 9746. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun, L. Breydo, N. Makarava, Q. Yang, O. V. Bocharova, and I. V. Baskakov Site-specific Conformational Studies of Prion Protein (PrP) Amyloid Fibrils Revealed Two Cooperative Folding Domains within Amyloid Structure J. Biol. Chem., March 23, 2007; 282(12): 9090 - 9097. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Shamsir and A. R. Dalby {beta}-Sheet Containment by Flanking Prolines: Molecular Dynamic Simulations of the Inhibition of {beta}-Sheet Elongation by Proline Residues in Human Prion Protein Biophys. J., March 15, 2007; 92(6): 2080 - 2089. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Espinosa, O. Andreoletti, J. Castilla, M. E. Herva, M. Morales, E. Alamillo, F. D. San-Segundo, C. Lacroux, S. Lugan, F. J. Salguero, et al. Sheep-Passaged Bovine Spongiform Encephalopathy Agent Exhibits Altered Pathobiological Properties in Bovine-PrP Transgenic Mice J. Virol., January 15, 2007; 81(2): 835 - 843. [Abstract] [Full Text] [PDF] |